Business Wire

ZOLL Propaq M Selected by U.S. Air Force and U.S. Army as Their Deployable Vital Signs Monitor

Jaa

ZOLL® Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced today the receipt of a sole source contract from the Defense Logistics Agency to supply Propaq® M deployable vital signs monitors to the U.S. Air Force and the U.S. Army.

The Propaq M, selected as the joint “Product of Choice,” is an advanced vital signs transport monitor, with capabilities far beyond the Propaq Encore 206, which has been the tried and trusted vital signs monitor serving the U.S. military over the last 25 years.

The Propaq M was designed specifically for the rigors of military operations in the most austere environments. The Propaq M can be equipped with an integrated defibrillator and pacer for critical lifesaving mission readiness. This configuration, known as the Propaq MD, eliminates the need to carry a separate monitor and defibrillator to improve operational efficiencies. During the competitive evaluation period, military subject matter experts stressed the importance of printing the 12 Lead ECG report and related patient data directly from the vital signs monitor. The Propaq M is the only airworthy vital signs monitor that is available with an integrated printer, thereby allowing the services to reduce size, weight and cube by eliminating the need to carry a separate standalone printer.

“We are very pleased to see the continued commitment to the ZOLL Propaq platform,” said A. Ernest Whiton, President of ZOLL’s global Resuscitation division. “This recent award demonstrates the DoD’s confidence in ZOLL’s monitoring and monitoring/defibrillation technology that is currently deployed throughout the services today.”

The Propaq M now joins several other ZOLL airworthy products selected by the services as their standard critical care transport medical device, further enhancing Defense Healthcare’s goal for interoperability throughout all roles of care in the U.S. Navy, the U.S. Air Force, the U.S. Marine Corps, and the U.S. Army from Medevac to strategic critical care airlift missions worldwide.

The Propaq M is equipped with the complete advanced Masimo® rainbow® SET® technology, including total hemoglobin (SpHb®) and pleth variability index (PVI®) along with advanced physiologic monitoring with three integrated invasive blood pressure channels. The Propaq M offers robust data communication and remote viewing capabilities. This remote viewing capability, currently installed on the USNS Comfort and USNS Mercy, has been instrumental in recent humanitarian missions to the Caribbean, Central America, and Asia Pacific regions of the world.

The Propaq M now joins several other ZOLL airworthy products selected by the services as their standard critical care transport medical devices including:

  • The Propaq MD ultra-lightweight, airworthy monitor/defibrillator that provides advanced monitoring capabilities, including full Masimo® Rainbow® SET technology and data transmission capabilities
  • The EMV+® 731 Series portable transport ventilator designed specifically for the U.S. military
  • The 330 Aspirator, the next generation in “smart” airworthy aspirators
  • The SMEED™ critical care platform designed to secure ZOLL monitors, monitor defibrillators, ventilators, and aspirators to standard NATO litters.

About ZOLL Medical Corporation
ZOLL Medical Corporation, an Asahi Kasei Group Company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, therapeutic temperature management, and ventilation, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and acute critical care. For more information, visit www.zoll.com.

About Asahi Kasei
The Asahi Kasei Group is a diversified group of companies led by holding company Asahi Kasei Corp., with operations in the material, homes, and health care business sectors. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals and diagnostic reagents. With more than 30,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries. For more information, visit www.asahi-kasei.co.jp/asahi/en/.

©2018 ZOLL Medical Corporation. All rights reserved. EMV+, SMEED, and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. Propaq is a registered trademark of Welch Allyn. Masimo, PVI, rainbow, SET, and SpHb are trademarks or registered trademarks of Masimo Corporation. All other trademarks are the property of their respective owners.

Contact information

ZOLL Medical Corporation
Diane Egan, +1-978-421-9637
degan@zoll.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Alibaba Cloud Expands European Presence With UK Data Centres22.10.2018 11:00Tiedote

Alibaba Cloud, the cloud computing arm of Alibaba Group, has today announced the opening of two availability zones in the UK, in addition to its Frankfurt and Dubai data centres launched in 2016. This expansion not only extends Alibaba Cloud’s capabilities within Europe, but also serves to highlight the provider’s ongoing commitment to the region. Alibaba Cloud’s local footprint is steadily increasing, with data centres across three EMEA locations: Frankfurt, Dubai, and now London. Answering an increase in demand for Alibaba Cloud services across the EMEA region, the pair of high performance availability zones will enable organisations in the region to accelerate the upgrade of their digital infrastructure enabling more efficient digital transformation initiatives. Business continuity is also a clear focus, with dual availability zones offering stronger disaster recovery capabilities. The London location also boasts 24/7 on-site support – including both security and engineering – as we

New Three-Year Data for Janssen’s TREMFYA®▼ (Guselkumab) Demonstrates Well Maintained Rates of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis22.10.2018 11:00Tiedote

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new long-term data from the open-label period of the VOYAGE 1 clinical study. The data demonstrate well maintained rates of skin clearance with TREMFYA®▼ (guselkumab) treatment at Week 52 (1 year) and Week 156 (3 years) among adult patients with moderate to severe plaque psoriasis.1 The findings, presented at the 37th Fall Clinical Dermatology Conference in Las Vegas, USA, showed nearly 83 percent of patients receiving guselkumab in the Phase 3 VOYAGE 1 study maintained at least a 90 percent improvement in the Psoriasis Area Severity Index (PASI 90), or near complete skin clearance, and an Investigator’s Global Assessment (IGA) score of cleared (0) or minimal disease (1) at Week 156.1 “These findings are impressive as they demonstrate consistency in high rates of skin clearance with guselkumab treatment at Weeks 48, 100 and 156, with every eight-week maintenance therapy,” said Andrew Blauvelt, MD, MBA, President,

Outline of New ESMO Guidelines Indicates Inclusion of FOTIVDA®▼ (Tivozanib) for Patients with Advanced Renal Cell Carcinoma22.10.2018 10:51Tiedote

EUSA Pharma (EUSA) welcomes the news that FOTIVDA®▼ (tivozanib) is expected to be included in the upcoming European Society of Medical Oncology (ESMO) clinical practice guidelines for advanced renal cell carcinoma (aRCC), anticipated to be published at the end of this year.1 The outline of the new proposed guidelines was presented on 19th October at the annual ESMO 2018 Congress in Munich, Germany, and indicated that tivozanib will be included as a first-line treatment recommendation for aRCC clear cell histology patients. The update will position tivozanib as a treatment standard for good (or favourable) risk patients with a Class IIa recommendation, and a treatment option for intermediate risk patients with a Class IIb recommendation.1 The indication of inclusion of tivozanib in the ESMO guidelines follows the grant of a European Commission (EC) licence in August 2017 for this oral, once-daily,a potent selective vascular endothelial growth factor receptor tyrosine kinase inhibitors (

Open Fiber Powers Its Optical Network With SM Optics WDM ROADM22.10.2018 10:00Tiedote

Open Fiber a national wholesales operator awards SM Optics, part of SIAE MICROELETTRONICA group a contract to supply and deploy WSS-free WDM ROADM technology extending fibre connectivity from their fibre backbone to metro/regional sites. The new network transports the FTTH (fibre-to-the-home) and FWA (Fixed-wireless-access) aggregated traffic, delivering ultra-broadband service to houses and local businesses. Open Fiber mission is to build a nationwide fiber network, bringing fibre connectivity to the vast majority of households and enterprises in the country, with a target of almost 19 million property units. This optical access infrastructure will enable operators delivering next generation services from FTTH broadband network for data, gaming, video streaming and mobile connectivity to 5G and IoT. SM Optics optical transport solution offers unprecedented flexibility in the smallest footprint, successfully meeting the challenge of limited space deployment and low power consumption. F

Zscaler Extends Cloud DLP Service with Inline Exact Data Match for Massive Data Sets Covering Users Globally22.10.2018 09:30Tiedote

Zenith Live Europe – Zscaler, Inc. (NASDAQ: ZS), the leader in cloud security, today announced inline Exact Data Match (EDM) with native SSL inspection as part of its advanced Cloud Data Loss Prevention (DLP) service. The inline EDM capability extends the Zscaler™ cloud platform to protect against the loss of sensitive information across all users and branches with more precision while reducing the number of false positives to near zero. This service is provided in the Zscaler cloud, providing the capacity of one billion data points per customer across 100 data centers globally. Traditional DLP appliances that sit in the data center are expensive and resource-intensive, and their protection can be subpar, often failing to alert an organization until after data has been compromised. Zscaler’s inline EDM with native SSL inspection blocks sensitive information before it leaves the network. In the first half of 2018, the Zscaler cloud platform blocked an average of 800,000 SSL-encrypted tr

Vivior Chairman Receives Award for Outstanding Contributions to Refractive Surgery22.10.2018 09:00Tiedote

Michael Mrochen, PhD, Chairman of the Board of Directors at Vivior, receives the Casebeer Award from the International Society of Refractive Surgery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181021005012/en/ Michael Mrochen, PhD Chairman of the Board of Directors Vivior AG (Photo: Business Wire) The International Society of Refractive Surgery (ISRS), a partner of the American Academy of Ophthalmology, is the leading worldwide organization for refractive surgeons. Each year, ISRS awards members for their special contributions to the ISRS, as well as their dedication to the field. The Casebeer Award recognizes an individual for his or her outstanding contributions to refractive surgery through nontraditional research and development activities (https://www.isrs.org/about-isrs/awards). Michael Mrochen is internationally known for his pioneering work on corneal laser surgery, corneal cross linking, ocular biometry and corn

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme